


Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: www.ajrcps.com



METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF CEFIXIME AND OFLOXACIN IN A PHARMACEUTICAL FORMULATION BY RP-HPLC METHOD

CH. Ravikumar*¹, V. Valli Kumari², G. Tuljarani³

*¹Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Dhulapally, Secunderabad, Andhra Pradesh, India.

ABSTRACT

An isocratic Simultaneous estimation by RP-HPLC Method were developed and validated for the quantification of Cefixime and Ofloxacin in tablet dosage form. Quantification was achieved by using a reversed-phase C18 column (INERTSIL Column, 5 μ , 250 mm \times 4.6 mm) at ambient temperature with mobile phase consisting of Ammonium acetate Buffer buffer: Acetonitrile: Methanol (50:30:20 pH:6.5)). The flow rate was 1.0 ml/min. Measurements were made at a wavelength of 226nm. The average retention time were found to be 2.39 min for Cefixime and 4.06 min for Ofloxacin. The proposed method was validated for selectivity, precision, linearity and accuracy. The assay methods were found to be linear from 60-140 μ g/ml for Cefixime and 60-140 μ g/ml for Ofloxacin. All validation parameters were within the acceptable range. The developed method was successfully applied to estimate the amount of Ofloxacin and Cefixime in tablet dosage form.

KEYWORDS

Cefixime, Ofloxacin, RP-HPLC method, Inertsil ODS Column, Different solvent such as Methanol, Acetonitrile, Ammonium acetate, Ortho phosphoric acid and Validation.

Author of correspondence:

CH. Ravikumar,
Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Dhulapally, Secunderabad, Andhra Pradesh, India.

Email: chaduvu.ravikumar@gmail.com.

INTRODUCTION

Ofloxacin (Figure No.1 (a)) a synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the super coiling activity of bacterial DNA gyrase, halting DNA replication. Ofloxacin acts on DNA gyrase and topoisomerase IV, enzymes which, like human topoisomerase, prevents the excessive super coiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell

division. Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of Ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an Ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of Ofloxacin. Side Effects: Headache, dizziness, dry mouth, nervousness and flushing¹.

Cefixime (Figure No.1 (b)) is an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall. Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime interferes with an autolysin inhibitor. Side Effects: drowsiness, sweating, dry mouth, headache, skin problems, lethargy, gastrointestinal irritation, hypersensitivity reactions, as well as movement problems/muscle rigidity and tremor².

MATERIALS AND METHOD

Instruments the chromatographic technique performed on a Shimadzu LC20-AT Liquid chromatography with SPD-20A prominence UV-visible detector and Spinchrom software, reversed phase C18 column (Inertsil 5 μ , 250 mm \times 4.6 mm) as stationary phase. Thermo Electron Corporation double beam UV-visible spectrophotometer (vision pro-software), Ultrasonic cleaner, Shimadzu analytical balance AY-220, Vacuum micro filtration unit with 0.45 μ membrane filter was used in the study.

MATERIALS

Pharmaceutically pure sample of Cefixime and Ofloxacin bulk drugs were obtained as gift samples

from Chandra laboratories Pvt Ltd, Prashanthi nagar, Kukatpally, Hyderabad, India. The purity of the drug was evaluated by obtaining its melting point and ultraviolet (UV) and infrared (IR) spectra. No impurities were found. The drug was used without further purification. HPLC-grade Acetonitrile and Methanol were from standard reagents Pvt Ltd. Ammonium acetate (AR grade) was from Merck. A tablet formulation of Cefixime and Ofloxacin bulk drugs (200 mg and 200mg label claims) was procured from local market (Milixime-O, Glenmark, India).

Determination of Working Wavelength (λ_{max})

10 mg of the Ofloxacin standard drug is taken in a 10 ml volumetric flask and dissolved in methanol and volume made up to the mark, from this solution 0.1ml is pipetted into 10 ml volumetric flask and made up to the mark with the methanol to give a concentration of 10 μ g/ml. The above prepared solution is scanned in uv between 200-400 nm using methanol as blank. The λ_{max} was found to be 281nm.

10 mg of the Cefixime standard drug is taken in a 10 ml volumetric flask and dissolved in methanol and volume made up to the mark, from this solution 0.1ml is pipetted into 10 ml volumetric flask and made up to the mark with the methanol to give a concentration of 10 μ g/ml. The above prepared solution is scanned in UV between 200-400 nm using methanol as blank. The λ_{max} was found to be 216nm. The iso bestic point of Ofloxacin and Cefixime were found to be 226nm (Figure No.2).

Preparation of mobile phase²⁻⁹

Buffer Preparation

3.85gm of Ammonium acetate was weighed and dissolved in 100ml of water and volume was made up to 1000ml with water. Adjust the pH to 6.5 using triethylamine. The buffer was filtered through 0.45 μ filters to remove all fine particles and gases.

Mobile phase

A mixture of 50 volumes of Ammonium acetate Buffer, 30 volumes of methanol and 20 volumes of Acetonitrile (HPLC grade). The mobile phase was sonicated for 10min to remove gases.

Analysis of formulation

Preparation of standard solution

A 100mg of standard Ofloxacin and 100 mg Cefixime were weighed and transferred to 50 ml of volumetric flask and dissolved in mobile phase. The flask was shaken and volume was made up to mark with mobile phase to give a primary stock solution containing 1000µg/ml Ofloxacin and 1000µg/ml of Cefixime. From the above solution 5ml of solution is pipetted out into a 50 ml volumetric flask and volume was made up to mark with mobile phase to give a solution containing 100µg/ml Ofloxacin and 100µg/ml of Cefixime.

Preparation of sample solution

For the estimation of the drug in tablet formulation twenty tablets were weighed and their average weight was determined. The tablets were then finely powdered. Appropriate quantity equivalent to 100mg Ofloxacin and 100 mg Cefixime were accurately weighed and The powder was transferred to 100 ml volumetric flask and shaken vigorously with mobile phase and sonicated for 15 min and volume made up to the mark with mobile phase. The solution was shaken vigorously and filtered by using whatmann filter no.41. from the above filtered clear solution 5ml of sample pipetted out into a 50 ml volumetric flask volume made up to the mark with mobile phase to give a solution containing 100µg/ml Ofloxacin and 100µg/ml of Cefixime. Calculation 5 replicates of each of sample and standard solutions were injected and their average peak areas were taken.

The amount of Ofloxacin and Cefixime present in the formulation by using the formula given below:-

$$\% \text{ Assay} = \frac{AT}{AS} \times \frac{WS}{DS} \times \frac{DT}{WT} \times \frac{P}{100} \times \frac{AW}{LC} \times 100$$

Where,

- AS: Average peak area due to standard preparation
- AT: Peak area due to assay preparation
- WS: Weight of standard drug taken
- WT: Weight of sample in assay preparation
- DT: Dilution of assay preparation
- DS: Dilution of standard preparation
- AW: Average weight of 20 tablets

Available online: www.uptodateresearchpublication.com

LC: Label claim

P: Purity of standard drug.

METHOD VALIDATION

Linearity

Linearity was studied by analyzing five standard solutions covering the range of 60-140µg/ml for Ofloxacin and 60-140 µg/ml for Cefixime of the drug. From the primary stock solution 0.6ml, 0.8ml, 1.0ml, 1.2ml, 1.4 ml of aliquots are pipetted into 10 ml volumetric flasks and made up to the mark with the mobile phase to give a concentrations of 60µg/mL, 80µg/mL, 100 µg/mL, 120µg/mL and 140µg/mL of Ofloxacin and 60µg/mL, 80µg/mL, 100 µg/mL, 120µg/mL and 140µg/mL mL of Cefixime (Table No.1 and 1.1).

Calibration curve (Figure No.3.1 and 3.2) with concentration verses peak areas was plotted by injecting the above prepared solutions and the obtained data were subjected to regression analysis using the least squares method.

Method precision (repeatability)

The precision of the instrument was checked by repeated injections and measurement of peak areas and retention times of solutions (n = 6) for, 100 µg/ml of Ofloxacin and 100 µg/ml of Cefixime without changing the parameter of the proposed chromatographic method.

Limit of detection and limit of quantification

The limit of detection (LOD) and limit of quantification (LOQ) were separately determined based on standard deviation of the y-intercept and the slope of the calibration curve by using the equations (2) and (3), respectively (Table No.2).

$$\text{LOD} = 3.3 \delta/S \dots\dots\dots (3)$$

$$\text{LOQ} = 10 \delta/S \dots\dots\dots (4)$$

Where,

- σ = the standard deviation of the response
- S = the slope of the calibration curve

The slope S may be estimated from the calibration curve of the analyte.

Accuracy (recovery study)

The accuracy of the method was determined by calculating the recoveries of Ofloxacin and Cefixime by the standard addition method. Known amounts of

standard solutions of Ofloxacin and Cefixime were added at 20% concentration to pre quantified sample solutions of Ofloxacin (100, 120, 140µg/ml) and Cefixime (100, 120, 140µg/ml). The amount of Ofloxacin and Cefixime recovered was estimated by using the following formulas (Table No.3 (a and b).

$$\% \text{ Recovery} = \frac{\text{amount found}}{\text{Amount added}} \times 100$$

$$\text{Amount Found (mcg / ml)} = \frac{\text{Mean test area} \times \text{Standard concentration}}{\text{Mean standard area}}$$

Specificity

In an assay, demonstration of specificity requires that it can be shown that the procedure is unaffected by the presence of impurities or excipients. In practice, this can be done by spiking the drug substance or product with appropriate levels of impurities or excipients and demonstrating that the assay results are unaffected by the presence of these extraneous materials. There should be no interference of the diluents, placebo at retention time of drug substances (Figure No.4).

Robustness

Robustness is the measure of a method remain unaffected by small, deliberate changes in method parameters like flow rate and detection wavelength on assay of the analyte of interest. Here the detection wavelength varied ± 2 nm and flow rate was varied ± 0.2 ml/min. The results were shown in (Table No.4).

Ruggedness

The ruggedness of the method was studied by analyzing the sample and standard preparations by two analysts. The % RSD assay values between two analysts was calculated i.e., (limit <2%).

This indicates the method was rugged. The results were shown in Table No.5.

RESULTS AND DISCUSSION

In RP HPLC method, the primary requirement for developing a method for analysis is that the using different solvents and buffers and columns to get better retention time and theoretical plates, and better cost effective and time saving method than the previously developed methods. The iso bestic point of Ofloxacin and Cefixime were found to be 226nm (Figure No.2) by scanning in UV region. The chromatographic method was optimized with mobile phase consisting of Ammonium acetate: Acetonitrile: Methanol (50:20:30) and C18 Inertsil column. All the validation parameters were studied at a wavelength 226nm. Accuracy was determined by calculating the recovery (Table No.3) and the results were in acceptable range (limit 98-102%). The method was successfully used to determine the amount of Ofloxacin and Cefixime present in the Tablet. The results obtained were in good agreement with the corresponding labeled amount (Table No.3). The method was linear in the concentration range of 60 to 140µg/ml for Ofloxacin and 60 to 140µg/ml for Cefixime (Table No.1 and 1.1 and Figure No.5). Robustness and ruggedness results were in acceptable range (Table No.4 and Table No.5). The assay was performed for both drug and the results showed in Table No.6 and Figure No.6 and 7). Precision was calculated as repeatability and intra and inter day variations (% RSD) for the drug (Table No.7 and 8). Summary of all validation parameters for method is given in Table No.9. By observing the validation parameters, the method was found to be simple, sensitive, accurate and precise. Hence the method can be employed for the routine analysis Ofloxacin and Cefixime in tablet dosage form.

Table No.1: Linearity of Ofloxacin

| S.No | Concentration (µg/ml) | Peak Area |
|------|-----------------------|-----------|
| 1 | 60 | 477.514 |
| 2 | 80 | 627.073 |
| 3 | 100 | 727.216 |
| 4 | 120 | 868.97 |
| 5 | 140 | 1018.025 |

Table No.1.1: Linearity of Cefixime

| S.No | Concentration (µg/ml) | Peak Area |
|------|-----------------------|-----------|
| 1 | 60 | 537.745 |
| 2 | 80 | 705.467 |
| 3 | 100 | 840.679 |
| 4 | 120 | 979.036 |
| 5 | 140 | 1158.544 |

Table No.2: LOD and LOQ values from calibration curve

| S.No | Cefixime | | Ofloxacin | |
|--------------|---------------------|-----------|---------------------|-----------|
| | Concentration µg/ml | Peak Area | Concentration µg/ml | Peak Area |
| 1 | 60 | 477.514 | 60 | 537.745 |
| 2 | 80 | 627.073 | 80 | 705.467 |
| 3 | 100 | 727.216 | 100 | 840.679 |
| 4 | 120 | 868.97 | 120 | 971.036 |
| 5 | 140 | 1018.025 | 140 | 1158.544 |
| S.D | 31.6 | 210 | 31.623 | 239 |
| Slope | 6.6 | | 7.535 | |

Table No.3(a): Recovery data for Cefixime

| S.No | Recovery level | Accuracy Cefixime | | | | | Average % Recovery |
|------|----------------|----------------------|----------|--------------|---------------------------|------------|--------------------|
| | | Amount taken(mcg/ml) | Area | Average area | Amount recovered (mcg/ml) | % Recovery | |
| 1 | 80% | 100 | 780.779 | 776.221 | 99.03 | 99.03 | 100.05% |
| | | 100 | 767.105 | | | | |
| | | 100 | 780.779 | | | | |
| 2 | 100% | 120 | 874.332 | 876.445 | 120.52 | 100.43 | |
| | | 120 | 877.992 | | | | |
| | | 120 | 877.012 | | | | |
| 3 | 120% | 140 | 1029.217 | 1020.963 | 140.99 | 100.71 | |
| | | 140 | 1018.025 | | | | |
| | | 140 | 1015.646 | | | | |

Table No.3(b): Recovery data for Ofloxacin

| S.No | Recovery level | Accuracy Ofloxacin | | | | | Average % Recovery |
|------|----------------|-----------------------|----------|--------------|---------------------------|------------|--------------------|
| | | Amount taken (mcg/ml) | Area | Average area | Amount recovered (mcg/ml) | % Recovery | |
| 1 | 80% | 100 | 876.196 | 873.127 | 99.01 | 99.01 | 99.58% |
| | | 100 | 866.989 | | | | |
| | | 100 | 876.196 | | | | |
| 2 | 100% | 120 | 987.754 | 988.846 | 117.62 | 98.02 | |
| | | 120 | 986.68 | | | | |
| | | 120 | 992.103 | | | | |
| 3 | 120% | 140 | 1173.701 | 1161.750 | 142.40 | 101.71 | |
| | | 140 | 1158.544 | | | | |
| | | 140 | 1153.004 | | | | |

Table No.4: Results of Robustness study

| S.No | Parameter | Cefixime | | Ofloxacin | |
|------|-------------------|----------------------|----------------|---------------------|----------------|
| | | Retention time (min) | Tailing factor | Retention time(min) | Tailing factor |
| 1 | Flow Rate | | | | |
| | 0.8 ml/min | 2.983 | 1.704 | 5.080 | 1.400 |
| | 1.0 ml/min | 2.410 | 1.783 | 4.083 | 1.594 |
| | 1.2 ml/min | 2.043 | 1.650 | 3.450 | 1.464 |
| 2 | Wavelength | | | | |
| | 224nm | 2.407 | 1.696 | 3.590 | 1.424 |
| | 226nm | 2.410 | 1.783 | 4.083 | 1.594 |
| | 228nm | 2.390 | 1.652 | 4.087 | 1.382 |

Table No.5: Results of Ruggedness

| S.No | Cefixime | % Assay | Ofloxacin | % Assay |
|------|------------|---------|------------|---------|
| 1 | Analyst 01 | 100.07 | Analyst 01 | 99.50 |
| 2 | Anaylst 02 | 100.2 | Anaylst 02 | 99.70 |
| 3 | % RSD | 0.09% | % RSD | 0.141% |

Table No.6: Assay Results

| S.No | Cefixime | | | Ofloxacin | |
|------------------------------|--------------|---------------|-------------|---------------|-------------|
| | Injections | Standard Area | Sample Area | Standard Area | Sample Area |
| 1 | Injection-1 | 766.15 | 767.951 | 870.067 | 866.991 |
| 2 | Injection-2 | 767.386 | 769.224 | 873.384 | 866.11 |
| 3 | Injection-3 | 770.258 | 770.067 | 870.812 | 869.701 |
| 4 | Injection-4 | 767.029 | 770.197 | 876.733 | 860.68 |
| 5 | Injection-5 | 769.113 | 766.992 | 863.079 | 876.514 |
| 6 | Average Area | 767.987 | 768.886 | 870.815 | 867.9992 |
| Tablet average weight | | 720.1mg | | 720.1mg | |
| Standard weight | | 50 mg | | 50 mg | |
| Sample weight | | 180.2mg | | 180.2mg | |
| Label amount | | 200 mg | | 200 mg | |
| Std.purity | | 99.6 | | 99.8 | |
| Amount found in mg | | 199.24 mg | | 198.76 mg | |
| Assay (% Purity) | | 99.62 % | | 99.38 % | |

Table No.7: Method Precision (Repeatability)

| S.No | Cefexime | | Ofloxacin | |
|---------------|----------|---------|-----------|---------|
| | Rt | Area | Rt | Area |
| 1 | 2.427 | 777.216 | 4.110 | 866.679 |
| 2 | 2.393 | 770.533 | 4.067 | 873.18 |
| 3 | 2.383 | 763.404 | 4.057 | 863.577 |
| 4 | 2.410 | 763.692 | 4.083 | 859.668 |
| 5 | 2.403 | 762.503 | 4.080 | 863.186 |
| 6 | 2.383 | 764.619 | 4.057 | 866.021 |
| Avg | 2.3998 | 766.995 | 4.076 | 865.385 |
| St.dev | 0.0171 | 5.773 | 0.020 | 4.553 |
| % RSD | 0.71 | 0.75 | 0.49 | 0.53 |

Table No.8: Intraday Precision

| S.No | Cefexime | | Ofloxacin | |
|-------|------------|----------|-----------|----------|
| | Rt | Area | Rt | Area |
| 1 | 2.400 | 769.362 | 4.025 | 866.254 |
| 2 | 2.401 | 765.565 | 4.085 | 867.352 |
| 3 | 2.403 | 763.254 | 4.025 | 865.988 |
| 4 | 2.401 | 769.328 | 4.096 | 864.285 |
| 5 | 2.391 | 766.222 | 4.098 | 863.985 |
| 6 | 2.396 | 768.521 | 4.021 | 865.321 |
| avg | 2.3987 | 767.0420 | 4.0583 | 865.5308 |
| stdev | 0.0044121 | 2.449429 | 0.038261 | 1.267624 |
| % RSD | 0.18393988 | 0.319334 | 0.942764 | 0.146456 |

Interday Precision

| S.No | Cefexime | | Ofloxacin | |
|-------|------------|----------|-----------|----------|
| | Rt | Area | Rt | Area |
| 1 | 2.458 | 769.854 | 4.025 | 864.251 |
| 2 | 2.453 | 769.325 | 4.036 | 863.241 |
| 3 | 2.451 | 766.501 | 4.021 | 867.212 |
| 4 | 2.469 | 767.451 | 4.085 | 866.325 |
| 5 | 2.478 | 769.52 | 4.087 | 866.854 |
| 6 | 2.495 | 764.458 | 4.091 | 867.542 |
| avg | 2.4673 | 767.8515 | 4.0575 | 865.9042 |
| stdev | 0.01697842 | 2.119679 | 0.033465 | 1.74915 |
| % RSD | 0.68812825 | 0.276053 | 0.824767 | 0.202003 |

Table No.9: Validation parameters of evaluated method

| S.No | Parameter | Limit | Value Obtained |
|------|---|---|--|
| 1 | Accuracy (% Recovery) | 98-102% | 99.58 % (Ofloxacin) 100.05% (Cefexime) |
| 2 | Linearity concentrations Range (µg/mL) Regression coefficient (R2 value) | NLT 0.99% | 60 to 140 µg/ml (Ofloxacin) R ² =0.996 and 60 to 140 µg/ml (Cefexime) R ² =0.9962 |
| 3 | Precision (% RSD) Method precision(Repeatability) (%RSD, n = 6) | NMT 1%(For Rt) NMT 2%(For Area) | %RSD of Rt=0.71% and %RSD of Area 0.75% (Ofloxacin) %RSD of Rt=0.49% and %RSD of Area 0.53% (Cefexime) |
| 4 | Intermediate Precision | - | - |
| 5 | Robustness(% assay) | It should be meet system suitability Parameters | Met the acceptance criteria |
| 6 | Ruggedness (% RSD analyst to analyst variation) | NMT 2% | % RSD of Ofloxacin:0.09% % RSD of Ofloxacin:0.141% |

aSD=Standard deviation, bLOD = Limit of detection, cLOQ = Limit of quantification, dRSD = Relative standard deviation.




Figure No.1 (a): Structure of Ofloxacin




Figure No.1 (b): Structure of Cefexime




Figure No.2: Determination of Isobestic Point





Figure No.3.1 and 3.2: Linearity (calibration) curve of Ofloxacin and Cefexime







Figure No.4: Chromatograms of Specificity (placebo, blank preparations)






Figure No.5: Chromatograms of Linearity




Figure No.6: Chromatogram of Assay sample preparation




Figure No.7: Chromatogram of assay standard preparation

CONCLUSION

The proposed Simultaneous Estimation by RP-HPLC method was found to be simple, sensitive, accurate and precise for determination of Ofloxacin and Cefixime in tablet. The method utilizes easily available and cheap solvent for analysis of Ofloxacin and Cefixime hence the method was also economic for estimation of Ofloxacin and Cefixime from Tablet. The common excipients and other additives are usually present in the Tablet mixture does not interfere in the analysis of Ofloxacin and Cefixime; hence it can be conveniently adopted for routine

quality control analysis of the drug in pharmaceutical formulation.

ACKNOWLEDGEMENT

The authors are sincerely thankful to the Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Dhulapally, Secunderabad, Andhra Pradesh, India for providing the facilities to complete this research work.

BIBLIOGRAPHY

1. www.wikipedia.org/wiki/Ofloxacin.
2. www.wikipedia.org/wiki/Cefixime.

3. ICH, Q2A validation of analytical procedure: Methodology International Conference on Harmonization, Geneva, October 1994.
4. ICH, Q2B Validation of analytical procedure: Methodology International Conference on Harmonization, Geneva, March 1996.
5. Khan I U, Sharif S, Ashfaq M, Asghar M N. Simultaneous determination of potassium clavulanate and cefixime in synthetic mixtures by high-performance liquid chromatography, *J AOAC Int*, 91, 2008, 744-9.
6. Manna L, Valvo L. Development and validation of a fast reversed-phase ion-pairing liquid chromatographic method for simultaneous determination of eight cephalosporin antibiotics in pharmaceutical formulations, *Chromatographia*, 60, 2004, 645-9.
7. Rathinavel G, Mukherjee PB, Valarmathy J, Samuel Joshua L, Ganesh M, Sivakumar T, et al. Validated RP - HPLC method for simultaneous estimation of cefixime and cloxacillin in tablets, *E-J Chem*, 5, 2008, 648-51.
8. Shah PB, Pundarikakshudu K. Spectro photometric, difference spectroscopic and high-performance liquid chromatographic methods for the determination of cefixime in pharmaceutical formulations, *J AOAC Int*, 89, 2006, 987-94.
9. <http://www.medlineindia.com>.